L 651582
Alternative Names: CAI; Carboxyamidotriazole; EP 00151529; NSC 609974Latest Information Update: 25 Sep 2021
At a glance
- Originator Merck & Co
- Developer National Cancer Institute (USA)
- Class Antineoplastics; Small molecules; Triazoles
- Mechanism of Action Angiogenesis inhibitors; Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Ovarian cancer; Peritoneal cancer; Prostate cancer
Most Recent Events
- 23 Jul 2002 A study has been added to the adverse events and Cancer therapeutic trials section
- 14 Aug 2001 A clinical study in patients with solid tumours has been added to the Cancer therapeutic trials and adverse events sections
- 09 Nov 1999 A study has been added to the therapeutic trials, adverse events and pharmacokinetics sections